StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT)

Wed, 29 Jul 2026 06:53:02 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $20.00 price target on Altimmune (NASDAQ: ALT).

The analyst commented: "This morning, Altimmune announced positive topline results from the Phase 2 RECLAIM trial evaluating pemvidutide, a 1:1 glucagon/GLP-1 dual agonist, in moderate-to-severe alcohol use disorder (AUD) (link to deck). The trial met its primary endpoint — a statistically significant reduction from baseline in heavy drinking days (HDD) per week vs placebo (p=0.0014) at Week 24 of −4.20 (LS mean) for pemvidutide vs. −2.75 for placebo, a treatment difference of −1.45 (MMRM, p=0.0014) (Exhibit 1). Importantly, RECLAIM met both FDA-recognized registrational secondary

Form 8-K Altimmune, Inc. For: Jul 28

Tue, 28 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260728/26822216.html

Form 8-K Altimmune, Inc. For: Jul 28

Tue, 28 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260728/26822216.html

Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

Tue, 28 Jul 2026 07:00:57 -0400

Altimmune, Inc. (Nasdaq: ALT) announced topline results from its RECLAIM Phase 2 trial evaluating pemvidutide 2.4 mg in patients with moderate to severe alcohol use disorder (AUD), with the drug meeting its primary endpoint of reducing heavy drinking days (HDD) versus placebo.

The trial, which randomized approximately 100 patients 1:1 to receive either pemvidutide 2.4 mg or placebo once weekly for 24 weeks, showed a statistically significant reduction in HDD per week at week 24, with a least-squares mean difference of -1.45 (p=0.0014). Secondary endpoints were also met, including a two-level reduction in WHO Risk Drinking Levels, achieved by 64.4% of

Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

Tue, 28 Jul 2026 07:00:57 -0400

Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

Tue, 28 Jul 2026 07:00:57 -0400

Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

Tue, 28 Jul 2026 07:00:57 -0400

Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

Tue, 28 Jul 2026 07:00:57 -0400

Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial

Tue, 28 Jul 2026 07:00:57 -0400

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

Tue, 28 Jul 2026 07:00:00 -0400

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial

A generally favorable tolerability profile was observed in the trial

Conference call to be held today at 8:00 am ET

GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on

Leerink Starts Altimmune (ALT) at Outperform

Mon, 22 Jun 2026 06:35:06 -0400

(Updated - June 22, 2026 6:35 AM EDT)

Leerink initiates coverage on Altimmune (NASDAQ: ALT) with a Outperform rating and a price target of $10.00.

The analyst commented: "We are initiating coverage of Altimmune (ALT) with an Outperform rating and a $10 price target. ALT is a late clinical-stage biotech company developing pemvidutide, a once-weekly, balanced 1:1 GLP-1/glucagon dual receptor agonist, for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Pemvidutide is designed to combine GLP-1-driven appetite suppression, weight loss, and glycemic control with glucagon-mediated effects on lipolysis, energy expenditure, liver fat reduction, inflammation, and fibrosis, potentially

Leerink Starts Altimmune (ALT) at Outperform

Mon, 22 Jun 2026 06:35:06 -0400

(Updated - June 22, 2026 6:35 AM EDT)

Leerink initiates coverage on Altimmune (NASDAQ: ALT) with a Outperform rating and a price target of $10.00.

Form 8-K Altimmune, Inc. For: Jun 16

Tue, 16 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260616/26654077.html

Form 8-K Altimmune, Inc. For: Jun 16

Tue, 16 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260616/26654077.html